Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
22 Juillet 2024 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the appointment of Karen Mahoney as Chief Human Resources
Officer following the retirement of Heidi Hassen, who served as
Vericel’s Head of Human Resources since September 2010.
Ms. Mahoney joins Vericel with more than 20 years of experience
across the life sciences and medical device sectors, most recently
serving as Chief Human Resources Officer at Abiomed, a global
medical device company that was acquired by Johnson & Johnson
in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR
strategy and operations, driving talent selection, leadership
development and contributing to strong business performance across
the company. Following the acquisition, Ms. Mahoney served as a key
member of the integration team overseeing the transition of all
HR-related programs into Johnson & Johnson. Prior to Abiomed,
Ms. Mahoney held roles of increasing responsibility at PerkinElmer,
culminating with her position as Global Talent Leader.
“I am delighted to welcome Karen to Vericel,” said Nick
Colangelo, President and CEO of Vericel. “Karen has a strong track
record of building high-performing teams and driving strong
business results in high-growth organizations. I am confident that
her extensive strategic and executive leadership experience in the
Human Resources and medical technology fields will play an
instrumental role in driving continued organizational success for
Vericel in the years ahead.”
“I am honored to join Vericel and am excited for the opportunity
to build upon Vericel’s strong foundation as we continue to foster
a purpose-driven, patient-focused culture that attracts and retains
world-class talent,” said Ms. Mahoney, Chief Human Resources
Officer of Vericel. “I look forward to partnering with our talented
teams to support Vericel’s long-term growth and drive continued
value for our patients and our shareholders.”
Ms. Mahoney earned a B.A. in Marketing from Assumption College
and her M.B.A from Suffolk University.
About Vericel Corporation Vericel is a leading
provider of advanced therapies for the sports medicine and severe
burn care markets. The Company combines innovations in biology with
medical technologies, resulting in a highly differentiated
portfolio of innovative cell therapies and specialty biologics that
repair injuries and restore lives. Vericel markets three products
in the United States. MACI® (autologous cultured chondrocytes
on porcine collagen membrane) is an autologous cellularized
scaffold product indicated for the repair of symptomatic, single or
multiple full-thickness cartilage defects of the knee with or
without bone involvement in adults. Epicel® (cultured
epidermal autografts) is a permanent skin replacement for the
treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid® (anacaulase-bcdb), a biological orphan product
containing proteolytic enzymes, which is indicated for the removal
of eschar in adults with deep partial-thickness and/or
full-thickness burns. For more information, please visit
www.vcel.com.
Epicel and MACI are registered trademarks of Vericel
Corporation. NexoBrid is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2024 Vericel
Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Août 2023 à Août 2024